Axovant to Present at Two Upcoming Investor Conferences Sep 20, 2018 07:00AM
Axovant Sciences (AXON) PT Raised to $4 at Chardan Capital Markets Jun 7, 2018 01:37AM
Chardan Capital Markets Upgrades Axovant Sciences (AXON) to Neutral Citing Less Scope for Underperformance Jan 10, 2018 04:16AM
Axovant Sciences (AXON): Still Bearish - Chardan Oct 5, 2017 07:40AM
UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets Sep 26, 2017 09:52AM

Sep 21, 2017 11:53AM Axovant Sciences (AXON) Job Posting Could Suggest NDA Filing - Chardan Capital Markets
Sep 13, 2017 09:32AM Axovant Sciences (AXON): Reiterating Sell - Chardan
Jan 19, 2016 02:59PM Chardan Closes Biotie/Axovant (AXON) Preference Following Acorda Deal; Reaffirms at 'Sell'
Sep 25, 2015 10:05AM Axovant Sciences (AXON) Defended at RBC Capital
Aug 3, 2015 02:46PM Chardan Capital Affirms Axovant Sciences (AXON) at 'Sell'; Sees as Mispriced Following vTv Therapeutics (VTVT) IPO
Jul 27, 2015 08:47AM Chardan Capital Sees Axovant's (AXON) RVT-101 Only Costing $5M Upfront; 'Sell' Rating Affirmed
Jul 23, 2015 09:40AM Chardan Capital Trims PT on Axovant (AXON) to $9.50; News is Good, but 24+ Late-Stage Alzheimer's Drugs in Development
Jun 18, 2015 09:34AM Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)
Jun 18, 2015 08:30AM Chardan Capital Markets Starts Axovant Sciences (AXON) at Sell; RVT-101 Remains Overrated